At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 target
Drug / intervention
DEBlue vs Cypher vs BMSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Paclitaxel-Eluting PTCA-Balloon in Combination With the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease - Substudy Homburg/Saar
In Brief
A Phase 2 clinical trial evaluating DEBlue vs Cypher vs BMS for Coronary Artery Disease. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The aim of the PEPCAD III substudy is to assess the efficacy of the Paclitaxel-eluting DEBlue stent system in the treatment of stenoses in native coronary arteries compared to the Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to study the influence of both devices on endothelial function, coronary flow reserve, and stem cell mobilization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJul 2007
Primary CompletionMar 2009
Study CompletionNov 2009
TodayJul 2026
First PostedMay 15, 2007
Enrollment StartJul 1, 2007
Primary CompletionMar 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.1 years ago
Interventions
DEBlue vs Cypher vs BMSdevice
BMS vs DES vs DEB+BMS